Premium
Single daily dose treatment of anxiety with clobazam or dipotassium clorazepate.
Author(s) -
Wallis TD,
ValleJones JC,
Craven JR,
Hanks GW,
Stonier PD
Publication year - 1979
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1979.tb04679.x
Subject(s) - clobazam , benzodiazepine , medicine , anti anxiety agents , anxiety , anesthesia , diazepam , incidence (geometry) , visual analogue scale , psychiatry , epilepsy , physics , receptor , optics
1 Forty‐four clinically anxious patients entered a comparative double‐ blind trial of clobazam 20 mg, clobazam 30 mg and dipotassium clorazepate 15 mg, all drugs given as a single dose at night. 2 Assessment by the Hamilton Anxiety Scale, Morbid Anxiety Inventory (Salkind) and a Visual Analogue Scale showed a statistically significant improvement for all treatment groups after 2 weeks, with continued improvement after a further 2 weeks. 3 Daytime drowsiness was the commonest side‐effect in all treatment groups but there was a tendency for a lower incidence in patients on clobazam. There was no evidence of a dose‐related incidence of drowsiness in the clobazam 20 mg and 30 mg groups. Other side‐effects were few and nonspecific. 4 Clobazam is a 1,5‐benzodiazepine with an elimination half‐life of 18 hours. When given in single doses of 20‐30 mg at night it has an equivalent effect to dipotassium clorazepate 15 mg.